HBIG Still Anchors the Earliest Phase of HBV Transplant Prophylaxis
Long-term survival after liver transplantation for hepatitis B virus-related liver disease improved sharply once hepatitis B immunoglobulins entered routine practice in the 1990s and potent nucleos(t)ide analogues became available two decades later. The clinical logic behind that shift is straightforward: transplant removes the diseased native liver, but it does not erase the viral reservoir. Residual HBV can reappear in the graft unless replication is suppressed at the source and circulating virions are neutralized during the most vulnerable perioperative window.
Current practice reflects that biology. International and national guidance, including recommendations from EASL, ELITA, AASLD and the British Transplantation Society, supports antiviral therapy before transplantation, high-dose HBIG during the anhepatic phase, and combined HBIG plus nucleos(t)ide analogue prophylaxis after surgery to prevent HBV recurrence. In other words, the earliest transplant period remains the place where antibody-based protection still has a clear role.
The question is what to do after the graft has stabilized.
Why the Early Post-Transplant Window Still Matters
HBIG is not a curative therapy. It works as passive immunization, binding circulating hepatitis B surface antigen and reducing the chance that the transplanted liver will be exposed to active viral particles at the wrong moment. That mechanism is especially relevant during and immediately after transplantation, when immune disruption, operative stress, and changing drug exposure can create a narrow but dangerous opening for recurrence.
A high-dose strategy during the anhepatic phase is therefore not a ceremonial add-on. It is a biologically plausible bridge between pretransplant viral suppression and durable post-transplant control. The graft is newly implanted, the patient is immunosuppressed, and viral escape during this interval can set the stage for later recurrence. In that setting, an antibody infusion is doing real work.
Long-Term Maintenance Has Become Harder to Justify
Maintenance HBIG is a different proposition. It is costly, inconvenient, and increasingly difficult to defend as a lifelong default when modern nucleos(t)ide analogues have a high barrier to resistance. Earlier prophylaxis strategies were built in an era when antiviral options were less reliable and virologic breakthrough was more common. Today, suppressive oral therapy can maintain excellent control in many patients, which raises a practical question: does indefinite HBIG still add enough protection to justify the burden?
The abstract makes the dilemma explicit. HBIG maintenance has demonstrated benefit largely in the era of nucleos(t)ide analogues with a low barrier to resistance. Once potent oral antivirals became standard, the incremental value of continued immunoglobulin became less certain. That uncertainty has pushed many transplant centers to re-examine how long HBIG really needs to continue after surgery.
This is not a theoretical argument about convenience. It affects infusion schedules, patient adherence, cost, and resource use in transplant programs that already operate at the edge of complexity.
The Prophylaxis Strategy Is Evolving Around Viral Risk, Not Tradition
The modern HBV transplant protocol rests on two complementary defenses. First, suppress viral replication before surgery so the reservoir is as quiet as possible. Second, neutralize any residual antigen immediately around transplantation, when the allograft is most exposed. After that, the clinical value of continued HBIG depends on how much residual risk remains once potent oral therapy is in place.
A patient with well-controlled HBV on a high-barrier nucleos(t)ide analogue is very different from a patient with prior treatment failure or adherence concerns. The abstract does not provide subgroup data, but the clinical principle is obvious: maintenance decisions should be driven by virologic risk, not by inertia. If recurrence risk is already low under potent oral suppression, then indefinite passive immunization may offer diminishing returns.
Cost and Convenience Are Not Minor Issues in Transplant Care
Transplant medicine often tolerates complexity when the payoff is clear. Here, the trade-off is more difficult. HBIG maintenance means repeated administration of a biologic product that adds cost and logistical burden to a long-term treatment plan that already includes lifelong surveillance and immunosuppression. For patients, that can mean an extra layer of visits, injections, or infusion-center coordination on top of an already demanding regimen.
The abstract’s framing reflects a broader shift in transplant hepatology: once a therapy is no longer obviously essential for all patients, it has to earn its place. That does not make HBIG obsolete. It makes it a targeted intervention with a narrower rationale, most convincing when viral risk is highest and least convincing when long-term suppression is secure.
What Clinicians Still Need to Decide at the Bedside
For now, the strongest statement supported by the abstract is that HBIG remains foundational early and debatable later. High-dose use during the anhepatic phase aligns with the known biology of HBV recurrence prevention. Combined prophylaxis after transplantation remains guideline-supported. The open issue is duration, especially in the setting of modern nucleos(t)ide analogues with high resistance barriers.
This is where transplant hepatology now lives: not in whether HBIG ever mattered, but in how long its protection meaningfully adds to what potent oral antivirals already accomplish. The answer will likely differ by recipient risk, donor and recipient virology, prior treatment history, and center-level practice patterns. Any move toward HBIG de-escalation has to preserve the one outcome that matters most in this setting: durable graft protection without HBV recurrence.
The abstract leaves the field at a familiar inflection point. HBIG was essential when options were limited. Whether it remains necessary beyond the early post-transplant period now depends on how much additional protection it can still provide once modern antiviral suppression is already in place.